Healthcare News 30 September 2025

UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

Stock Price Snapshot: October 2025 Rebound UnitedHealth stock has seen volatile swings in 2025, but recent weeks brought a measure of relief. As of Oct. 21, shares trade around $364, up from

21 October 2025

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine

21 October 2025

Analyst Ratings · Biotechnology · Healthcare · Investment · NASDAQ:BEAM · Stock Market

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to

21 October 2025

Healthcare · Investing · Market News · Mergers & Acquisitions · NASDAQ:DCGO · Stocks

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the

18 October 2025

Biotechnology · Healthcare · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

Stock Price Surge and Aftermath INVO Fertility’s stock took Wall Street by surprise this week with a massive one-day surge. On October 16, shares of the micro-cap fertility clinic operator opened around

17 October 2025

Fertility · Healthcare · Investing · IVF · NASDAQ:INVO · Stock Market

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug

17 October 2025

Healthcare · Industry News · NASDAQ:AKRO · NASDAQ:OMER · NYSE:LLY · NYSE:NVO · Pharmaceuticals · Stock Market · Weight Loss

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Lawsuit Outcome and Court Ruling Humana (the second‐largest Medicare Advantage insurer) sued CMS in July after its star rating unexpectedly plunged. The insurer argued that CMS unfairly flagged three interpreter calls as

15 October 2025

Healthcare · Insurance · Legal News · Medicare · NYSE:HUM · Stock Market

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol,

14 October 2025

Business News · Corporate Strategy · Healthcare · Industry Trends · Medical Devices · NYSE:JNJ · NYSE:KVUE

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted

6 October 2025

Business News · Healthcare · Investment Trends · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharma Industry · Stock Market

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis

3 October 2025

Biotechnology · Healthcare · Investment News · NASDAQ:TARS · Pharmaceuticals · Stock Market

Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Stock Performance (Oct 3, 2025) As of midday Oct 3, Humana shares were $272.05, up about +6.01% on the day reuters.com. Yesterday’s close (Oct 2) was $256.62 reuters.com, so HUM has recovered much of last

3 October 2025

Financial News · Healthcare · Investing · Medicare · NYSE:HUM · Stock Market · Stocks

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx

30 September 2025

Healthcare · NYSE:PFE · Pharmaceuticals · Policy · Politics · US News

Healthcare News 30 September 2025 - 21 October 2025